MMI-0100

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C98H171N37O26
Molecular Weight	2283.6386
Optical Activity	UNSPECIFIED
Defined Stereocenters	21 / 21
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O

InChI

InChIKey=NXUWTKIOMJSLSV-DEEZXRHXSA-N

InChI=1S/C98H171N37O26/c1-45(2)41-68(84(150)115-44-72(139)135-73(47(5)6)93(159)124-50(9)76(142)125-57(16)94(160)161)134-91(157)67(33-35-71(102)138)132-90(156)65(27-22-40-114-98(109)110)130-81(147)55(14)123-92(158)69(42-46(3)4)133-82(148)56(15)121-85(151)61(23-17-18-36-99)126-79(145)53(12)120-87(153)63(25-20-38-112-96(105)106)128-80(146)54(13)122-88(154)66(32-34-70(101)137)131-89(155)64(26-21-39-113-97(107)108)129-77(143)51(10)117-74(140)48(7)116-75(141)49(8)119-86(152)62(24-19-37-111-95(103)104)127-78(144)52(11)118-83(149)60(100)43-58-28-30-59(136)31-29-58/h28-31,45-57,60-69,73,136H,17-27,32-44,99-100H2,1-16H3,(H2,101,137)(H2,102,138)(H,115,150)(H,116,141)(H,117,140)(H,118,149)(H,119,152)(H,120,153)(H,121,151)(H,122,154)(H,123,158)(H,124,159)(H,125,142)(H,126,145)(H,127,144)(H,128,146)(H,129,143)(H,130,147)(H,131,155)(H,132,156)(H,133,148)(H,134,157)(H,135,139)(H,160,161)(H4,103,104,111)(H4,105,106,112)(H4,107,108,113)(H4,109,110,114)/t48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,73-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C98H171N37O26
Molecular Weight	2283.6386
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	21 / 21
E/Z Centers	14
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 12:07:03 UTC 2023` Edited by `admin` on `Sat Dec 16 12:07:03 UTC 2023`
Record UNII	6VP6PBL1ZH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MMI-0100

Common Name

English

(2S)-2-(((2S)-2-(((2S)-2-((2-(((2S)-2-(((2S)-5-AMINO-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-6-AMINO-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-5-AMINO-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPANOYL)AMIN

Systematic Name

English

MMI 0100

Code

English

L-ALANINE, L-TYROSYL-L-ALANYL-L-ARGINYL-L-ALANYL-L-ALANYL-L-ALANYL-L-ARGINYL-L-GLUTAMINYL-L-ALANYL-L-ARGINYL-L-ALANYL-L-LYSYL-L-ALANYL-L-LEUCYL-L-ALANYL-L-ARGINYL-L-GLUTAMINYL-L-LEUCYLGLYCYL-L-VALYL-L-ALANYL-

Systematic Name

English

Code System Code Type Description

PUBCHEM

127043567

Created by admin on Sat Dec 16 12:07:04 UTC 2023 , Edited by admin on Sat Dec 16 12:07:04 UTC 2023

PRIMARY

CAS

1039342-24-9

Created by admin on Sat Dec 16 12:07:04 UTC 2023 , Edited by admin on Sat Dec 16 12:07:04 UTC 2023

PRIMARY

FDA UNII

6VP6PBL1ZH

Created by admin on Sat Dec 16 12:07:04 UTC 2023 , Edited by admin on Sat Dec 16 12:07:04 UTC 2023

PRIMARY

Related Record Type Details


					2EP8DE2BBS

MAP KINASE-ACTIVATED PROTEIN KINASE 2

TARGET -> INHIBITOR

Related Record Type Details


					6VP6PBL1ZH

MMI-0100

ACTIVE MOIETY

Comments:

MK2 is critical to the pathogenesis of ischemic heart injury as MK2(-/-) mice are resistant to ischemic remodeling. Therefore, we tested the hypothesis that inhibiting MK2 with MMI-0100 would protect the heart after acute myocardial infarction (AMI) in vivo. AMI was induced by placing a permanent LAD coronary ligation. When MMI-0100 peptide was given 30 min after permanent LAD coronary artery ligation, the resulting fibrosis was reduced/prevented ~50% at a 2 week time point, with a corresponding improvement in cardiac function and decrease in left ventricular dilation. In cultured cardiomyocytes and fibroblasts, MMI-0100 inhibited MK2 to reduce cardiomyocyte caspase 3/7 activity, while enhancing primary cardiac fibroblast caspase 3/7 activity, which may explain MMI-0100's salvage of cardiac function and anti-fibrotic effects in vivo. These findings suggest that therapeutic inhibition of MK2 after acute MI, using rationally-designed cell-permeant peptides, inhibits cardiac fibrosis and maintains cardiac function by mechanisms that involve inhibiting cardiomyocyte apoptosis, while enhancing primary cardiac fibroblast cell death.


					6VP6PBL1ZH

MMI-0100

ACTIVE MOIETY

Comments:

Originator: Moerae Matrix; Class: Anti-inflammatory, Antifibrotic, Peptide; Mechanism of Action: MAP-kinase-activated kinase 2 inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Available For Licensing: Yes; Highest Development Phases: Phase I for Idiopathic pulmonary fibrosis, No development reported for Fibrosis; Most Recent Events: 16 Jul 2016 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Inhalation), 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in USA, 28 Jul 2015 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in United Kingdom (Inhalation)